PathAI Announces 13 Lab Contracts for Its AI Tools
ePathAI (Boston, MA) has won contracts with 13 lab organizations that will be using its FDA-cleared AISight digital pathology image management and viewer analysis system. These new clients will also be using PathAI’s software algorithm AIM-PD-L1 NSCLC RUO, which quantitates the percentage of PD-L1 positive tumor and immune cells in non-small cell lung cancer samples.
Among the 13 labs that will be using PathAI’s AI-based software algorithms is PathAI Diagnostics (Memphis, TN)—formerly named Poplar Healthcare. PathAI acquired Poplar Healthcare in August 2021 (see LE, August 2021). PathAI Diagnostics is a full-service anatomic pathology lab with 350 employees, including 25 pathologists.
Other labs that will be using PathAI’s software tools include Caris Life Sciences, NeoGenomics and University of Pittsburgh Medical Center (see table below).
These labs will have early access to additional AI algorithms that PathAI expects to bring to market for research use only (RUO) within the next few months. These products include AI software tools for quantitative PD-L1 tests for melanoma, head and neck, and bladder cancer, as well as an
algorithm for the automated quantification of HER2 IHC images in breast cancer tissue.
Labs will have the potential to validate PathAI’s RUO products so that they can be used as lab-developed tests for clinical diagnostics, according to Andy Beck, MD, PhD, Chief Executive of PathAI.
The new clients were all signed by PathAI within the past six months. Beck anticipates more lab client announcements soon. Eric Walk, MD, Chief Medical Officer, and Parth Chodavadia, Head of Commercial, Digital Diagnostics, are leading the marketing efforts at PathAI.
PathAI has raised a total of $255 million since being formed in 2016. Major backers include Labcorp, Kaiser Permanente, Merck and Bristol Meyers, as well as the private equity firms General Atlantic and General Catalyst.